Event Date/Time: Jul 18, 2005
End Date/Time: Jul 18, 2005
Following the conclusion of the recent FDA hearings on the safety of COX-2 inhibitors, and as additional information comes to light about the potential for cardiac toxicity in other drug classes, the need for novel, out-of-the-box approaches to assess cardiac risk becomes more important. Cardiac Safety: From QT and COX-2s to the Future of Clinical Medicine offers the most current thinking on the topic, updating you on the ICH E14 guidance document and the proven views on QT prolongation. We then move beyond those perspectives to provide cutting edge, and even controversial research on cardiac toxicity that will help to guide the future of clinical medicine.
To register or view full details, visit www.IBCLifeSciences.com/3129 or call +1 508-616-5550 x1004.